Related Experiment Video
Updated: Sep 2, 2025
07:41
Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
Published on: May 17, 2019
9.1K
Oligometastatic breast cancer: An institutional analysis
Ajay Gogia1, Surya V S Deo2, Daya N Sharma3
1Department of Medical Oncology, All India Institute of Medical Sciences, New Delhi, India.
Indian Journal of Cancer
|August 10, 2022
Summary
Oligometastatic breast cancer (OMBC) accounts for 24% of metastatic breast cancer cases. Hormone receptor-positive patients with bone-only metastasis and surgery after neoadjuvant chemotherapy show improved outcomes.
Area of Science:
- Oncology
- Medical Research
Background:
- Oligometastatic breast cancer (OMBC) is a distinct subtype of metastatic breast cancer (MBC).
- Literature on OMBC, particularly from India, is limited, with an incidence of 1-5% in newly diagnosed MBC patients.
Purpose of the Study:
- To investigate the characteristics, treatment, and survival outcomes of oligometastatic breast cancer (OMBC) patients in India.
- To identify prognostic factors influencing progression-free survival (PFS) in OMBC.
Main Methods:
- A retrospective analysis of 120 OMBC patients diagnosed between January 2013 and August 2018.
- Data collected included clinical, pathological, receptor status (ER, PR, HER2/neu), radiological, treatment, and survival details.
Main Results:
- The incidence of OMBC was found to be 24% of all MBC cases.
- Hormone receptor positivity (ER/PR), bone-only metastasis, and post-neoadjuvant chemotherapy (NACT) surgery were associated with significantly better PFS.
- HER2/neu-positive patients receiving targeted therapy demonstrated improved PFS.
Conclusions:
- OMBC represents a significant proportion (24%) of MBC in the studied cohort.
- Favorable prognostic indicators for OMBC include hormone receptor positivity, bone-only metastasis, and surgical intervention post-NACT.
